• Questions? +1 (732) 747-1007
  • ir@americancryostem.com
  • Physicians
  • Licensing & Partners
American CryoStem, Stem Cell TherapyAmerican CryoStem, Stem Cell TherapyAmerican CryoStem, Stem Cell TherapyAmerican CryoStem, Stem Cell Therapy
  • SERVICES
    • HOW IT WORKS
    • COSMETIC CRYO-FAT
    • ADULT STEM CELLS
  • PRODUCTS
    • TISSUE HARVESTING SYSTEM
    • STEM CELL MEDIAS
    • STEM CELL LINES
  • OUR SCIENCE
    • LONG COVID CLINICAL TRIAL
  • INVESTORS
    • ABOUT US
    • STOCK INFORMATION
    • PRESS RELEASES
    • OUR LEADERSHIP
    • LICENSING PARTNERS
  • NEWS
  • CONTACT

American CryoStem Appoints Dr. Mel Bircoll to its Medical Advisory Board

December 6, 2012

EATONTOWN, N.J., Dec. 6, 2012 (GLOBE NEWSWIRE) — American CryoStem Corporation (CRYO), a leading biotech company in the Regenerative Medicine industry, announced today the appointment of Dr. Mel Bircoll to its Medical Advisory Board. Dr. Bircoll will be taking an active role on the Advisory Board to lead the development of the Company’s educational and informational programs focused on adipose tissue transfer and storage.

Dr. Bircoll is board certified by the American Board of Plastic Surgery and the American Board of Cosmetic Surgery. He is a member of the American Society of Plastic Surgery and the American Academy of Cosmetic Surgery. He is widely known as the first Plastic Surgeon to perform Liposuction in North America.

Since the 1980’s he has pioneered and championed liposuction procedures from its early beginnings to it becoming the most frequently performed cosmetic procedure. He is also the originator of fat transfer (autologous fat transplantation). His landmark presentation: “Fat Transfer Using Liposuction Techniques” (1984), established this procedure for breast augmentation, facial and hand rejuvenation, as well as a host of reconstructive procedures commonly used by surgeons today.

John S. Arnone, CEO stated, “As an active working member of our Medical Advisory Board, we will benefit from his tremendous industry recognition as one of the leading authorities on adipose tissue transfer applications. His capability to guide long-term success in the rapidly developing adipose tissue transfer market in an increasingly regulated business environment is an invaluable assist to the Company and its shareholders. Dr. Bircoll will also lead the national expansion of our tissue storage platform to physicians, adopting new adipose tissue transfer and storage services for their patients.”

Mr. Arnone further commented, “The added advantage of our platform is that, every stored tissue sample may be retrieved and further processed in the future into an expanded clinical stem cell sample for use in the Cellular Therapy and Regenerative Medicine industry.”

Dr. Bircoll is retired from 25 years of private practice in Beverly Hills, California and is currently lecturing and teaching the techniques of fat transfer and fat storage for stem cell extraction, as well as cosmetic and reconstructive applications. His latest research presents the use of serial injections of cryopreserved autologous adipose tissue for breast reconstruction following cancer prevention surgery.

“I am very excited by the opportunity to expand my lecture and teaching activities to my associates and peers that are focused on tissue transfer and tissue storage. The ability to clinically store fat tissue will revolutionize the tissue transfer market and lead to better economics and increased procedures for all providers,” stated Mel Bircoll. “Since I began championing these procedures, I have always recognized the need to provide a better service to patients through the ability to access multiple tissue grafting procedures while performing a single tissue harvest. American CryoStem’s ability to properly collect, process, test and store tissue in a clinical setting, their attention to regulations and, their internal quality management methods makes them the “Gold Standard” of the tissue banking service providers.”

About American CryoStem: American CryoStem Corporation (CRYO) is a leading biotech company focused on marketing its clinical processing services and patented products for adipose (fat) tissue and adipose derived adult stem cells. Our clinical tissue processing, patented cell culture media products and tissue storage platform supports cosmetic and regenerative medicine applications being developed globally. The Company provides high quality, clinically processed viable cells, while at the same time developing cutting edge applications, therapies, patented laboratory products and services for consumer and commercial applications.

Contact:

Investor Relations Contact:
American CryoStem Corporation
732-747-1007
info@americancryostem.com
www.americancryostem.com

Share

Related posts

January 6, 2023

American CryoStem Announces FDA Approval of IND to Commence Phase I Clinical Trial for Long COVID/Post-Acute Sequelae of SARS-CoV-2 (PASC)


Read more
December 22, 2022

American CryoStem Announces the Addition of Agustin Legido, MD, PhD, MBA to its Advisory Board


Read more
March 4, 2022

American CryoStem Announces Patient Treatment Status for its Phase I Clinical Trial for Post-Concussion Syndrome (PCS)


Read more

About American CryoStem Corporation

American CryoStem Corporation (OTC:CRYO), is a clinical-stage biotechnology company, global licensor and a pioneer in autologous (one’s own) cellular processing and therapies. The Company's centralized laboratory model and patented foundational “CryoStem Platform” is a best-in-class, end-to-end cellular therapy solution to treat injuries, disorders and chronic diseases through a single adipose-tissue (fat) harvest and ATCELLBank™ cryopreservation. We are dedicated to helping the world’s physicians, hospitals, and clinics improve clinical outcomes by developing and delivering effective leading-edge stem cell therapies that improve patient health and quality of life.

© 2021 American CryoStem Corporation | A Publicly Traded Company (CRYO)
  • Physicians
  • Licensing & Partners